Live cumulative network meta-analysis: Protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor

BMJ Open

Volumn 6, Issue 8, 2016, Pages

  Créquit, Perrine ^a,b   Trinquart, Ludovic ^a,b,c,d   Ravaud, Philippe ^a,b,c,d,e  

^a PARIS DESCARTES UNIVERSITY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔTEL DIEU   (France)

^d Cochrane France ^*  (France)

^e Columbia University New York ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CROWDSOURCING; HUMAN; MEDICAL HISTORY; META ANALYSIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; CLINICAL DECISION MAKING; DISEASE FREE SURVIVAL; LUNG TUMOR; METHODOLOGY; NETWORK META-ANALYSIS; PROOF OF CONCEPT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL DECISION-MAKING; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; NETWORK META-ANALYSIS; PROOF OF CONCEPT STUDY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN;

EID: 84981492689     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-011841     Document Type: Article

References (51)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. US Food and Drug Administration. Highlights of prescribing information: CYRAMZA (ramucirumab). http://www.accessdata.fda. gov/drugsatfda-docs/label/2014/125477s007lbl.pdf
3. US Food and Drug Administration. Highlights of prescribing information: OPDIVO (nivolumab). http://www.accessdata.fda.gov/ drugsatfda-docs/label/2015/125527s000lbl.pdf
4. Haidich AB, Pilalas D, Contopoulos-Ioannidis DG, et al. Most meta-Analyses of drug interventions have narrow scopes and many focus on specific agents. J Clin Epidemiol 2013;66:371-8.
5. Créquit P, Trinquart L, Yavchitz A, et al. Wasted research when systematic reviews fail to provide a complete and up-To-date evidence synthesis: the example of lung cancer. BMC Med 2016;14:8.
6. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-Analysis. Ann Intern Med 2013;159:130-7.
7. Hawkins N, Scott DA, Woods BS, et al. No study left behind: a network meta-Analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. Value Health 2009;12:996-1003.
8. Popat S, Mellemgaard A, Fahrbach K, et al. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-Analysis. Future Oncol 2015;11:409-20.
9. Shojania KG, Sampson M, Ansari MT, et al. How quickly do systematic reviews go out of date?. A survival analysis. Ann Intern Med 2007;147:224-33.
10. Polisena J, Garritty C, Kamel C, et al. Rapid review programs to support health care and policy decision making: a descriptive analysis of processes and methods. Syst Rev 2015;4:26.
11. Elliott JH, Turner T, Clavisi O, et al. Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap. PLoS Med 2014;11:e1001603.
12. Vandvik PO, Brignardello-Petersen R, Guyatt GH. Living cumulative network meta-Analysis to reduce waste in research: a paradigmatic shift for systematic reviews?. BMC Med 2016;14:59.
13. Comparing Multiple Interventions Methods Group. Protocol template for a Cochrane intervention review that compares multiple interventions. 2014. http://methods.cochrane.org/cmi/sites/methods. cochrane.org.cmi/files/uploads/Protocol%20for%20Cochrane%20Reviews%20with%20Multiple%20Interventions.pdf
14. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-Analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84.
15. Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 2015;33:1000-7.
16. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015;33:3488-515.
17. Di Maio M, Chiodini P, Georgoulias V, et al. Meta-Analysis of single-Agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009;27:1836-43.
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Chan AW. Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ 2012;344:d8013.
20. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaborations tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
21. Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9.
22. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-Treatment meta-Analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
23. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-Analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 2012;41:818-27.
24. Turner RM, Jackson D, Wei Y, et al. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-Analysis. Stat Med 2015;34:984-98.
25. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta-Analyses of continuous outcome data. J Clin Epidemiol 2015;68:52-60.
26. Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013;33:641-56.
27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. BMJ 2009;339:b2535.
28. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Updated March. 2011. http://handbook.cochrane.org
29. Decatris MP, Farrugia D, O'Byrne KJ. Clinician perspective on molecular profiling of non-small-cell lung cancer. J Clin Oncol 2016;34:884-6.
30. Smalheiser NR, Lin C, Jia L, et al. Design and implementation of Metta, a metasearch engine for biomedical literature retrieval intended for systematic reviewers. Health Inf Sci Syst 2014;2:1.
31. Maruani A, Boutron I, Baron G, et al. Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial. BMJ 2014;349:g5579.
32. Tasneem A, Aberle L, Ananth H, et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS ONE 2012;7:e33677.
33. Marshall IJ, Kuiper J, Wallace BC. Automating risk of bias assessment for clinical trials. IEEE J Biomed Health Inform 2015;19:1406-12.
34. Millard LA, Flach PA, Higgins JP. Machine learning to assist risk-of-bias assessments in systematic reviews. Int J Epidemiol 2016;45:266-77.
35. Del Giovane C, Vacchi L, Mavridis D, et al. Network meta-Analysis models to account for variability in treatment definitions: application to dose effects. Stat Med 2013;32:25-39.
36. Mosseri J, Trinquart L, Nizard R, et al. Meta-Analysis of a complex network of non-pharmacological interventions: the example of femoral neck fracture. PLoS ONE 2016;11:e0146336.
37. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-Analysis. Stat Med 2011;30:903-21.
38. Nikolakopoulou A, Mavridis D, Salanti G. Prospective use of network meta-Analysis using formal statistical monitoring. 36th Annual Conference of the International Society for Clinical Biostatistics; 23-27 August 2015. Utrecht, The Netherlands.
39. Pulverer B. EMBO Press-A new way to publish. EMBO J 2014;33:1-2.
40. Rathbone J, Hoffmann T, Glasziou P. Faster title and abstract screening?. Evaluating Abstrackr, a semi-Automated online screening program for systematic reviewers. Syst Rev 2015;4:80.
41. Tsafnat G, Dunn A, Glasziou P, et al. The automation of systematic reviews. BMJ 2013;346:f139.
42. Tsafnat G, Glasziou P, Choong MK, et al. Systematic review automation technologies. Syst Rev 2014;3:74.
43. Miwa M, Thomas J, O'Mara-Eves A, et al. Reducing systematic review workload through certainty-based screening. J Biomed Inform 2014;51:242-53.
44. O'Mara-Eves A, Thomas J, McNaught J, et al. Using text mining for study identification in systematic reviews: a systematic review of current approaches. Syst Rev 2015;4:5.
45. Wallace BC, Trikalinos TA, Lau J, et al. Semi-Automated screening of biomedical citations for systematic reviews. BMC Bioinformatics 2010;11:55.
46. Llewellyn A, Whittington C, Stewart G, et al. The use of Bayesian networks to assess the quality of evidence from research synthesis: 2. Inter-rater reliability and comparison with standard GRADE assessment. PLoS ONE 2015;10:e0123511.
47. Stewart GB, Higgins JP, Schünemann H, et al. The use of Bayesian networks to assess the quality of evidence from research synthesis: 1. PLoS ONE 2015;10:e0114497.
48. Shanahan DR. A living document: reincarnating the research article. Trials 2015;16:151.
49. Open Meta Analysis. http://openmetaanalysis.github.io
50. OpenTrials All the Data oAtT, Linked. http://opentrials.net
51. Mo Y, Kontonatsios G, Ananiadou S. Supporting systematic reviews using LDA-based document representations. Syst Rev 2015;4:172.